Healthcare Industry News: influenza
News Release - December 14, 2010
Pulmatrix Names Eva Jack as Chief Business OfficerJack chosen to develop and execute Commercial and Business Development Strategies
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)-- Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the appointment of Eva Jack as Chief Business Officer. In this newly created position, Ms. Jack will provide strategic leadership as the Company begins business development efforts around its portfolio of proprietary inhaled cationic airway lining modulator (iCALM) drugs and pulmonary drug delivery platform.
“Eva is a proven leader and has the vision and skill set required to navigate the broad set of opportunities we now have with our unique iCALM products and platform technology,” said Robert Connelly, CEO of Pulmatrix. “She brings to Pulmatrix a unique blend of experiences in life sciences investing and business development and in the building of entrepreneurial companies, and we feel fortunate to have her as part of the management team.” Pulmatrix expects to establish initial partnerships in the first half of 2011. The Company currently has an iCALM drug in a Phase 1 trial in asthmatics and expects to initiate a Phase 1 trial in COPD patients in Q1 2011.
Ms. Jack most recently served as Managing Director at MedImmune Ventures, the corporate venture fund of MedImmune, LLC, which included serving as a board member or board observer for several portfolio companies. She initially joined MedImmune’s business development group serving as Director and Associate Director, completing numerous in-licensing and out-licensing transactions. Prior to her tenure at MedImmune, she held various senior leadership positions at Intel Corporation, including Senior Manager of Strategic Investments. Ms. Jack earned her Masters of Health Science from Johns Hopkins and her B.A. in Communications from the University of Virginia.
“iCALM therapies have transformational potential for patients, and now it is a matter of sharing our insights and knowledge to ensure we capture the full value of our assets to rapidly advance these therapies,” said Jack. “The company is backed by a fantastic group of investors, Directors, and scientific advisors and the additional funding from NIAID and DARPA supports our belief in the broad and novel potential of our iCALM drugs. I look forward to contributing my experience and insights at this exciting stage of the Company’s development.”
Pulmatrix is discovering and developing a new class of therapies --inhaled cationic airway lining modulators (iCALM) –to prevent and treat respiratory infections and acute exacerbations of chronic respiratory diseases. iCALM therapies have broad potential to treat and prevent a wide range of respiratory diseases, including respiratory infections such as influenza; ventilator associated pneumonia (VAP) and respiratory syncytial virus (RSV), as well as progressive or chronic respiratory diseases such as COPD, asthma, and cystic fibrosis. For additional information about the Company, please visit http://www.pulmatrix.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.